Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease

被引：147

作者：

Müller, T ^{[1
]}

Büttner, T ^{[1
]}

Gholipour, AF ^{[1
]}

Kuhn, W ^{[1
]}

机构：

[1] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-44791 Bochum, Germany

来源：

NEUROSCIENCE LETTERS | 2003年 / 341卷 / 03期

关键词：

coenzyme Q(10); pharmacotherapy; Parkinson's disease; visual dysfunction;

D O I：

10.1016/S0304-3940(03)00185-X

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Features of Parkinson's disease (PD) include oxidative stress, nigral mitochondrial complex I deficiency and visual dysfunction, all of which are also associated with coenzyme Q(10) (CoQ(10)) deficiency. The objective of this monocenter, parallel group, placebo controlled, double-blind trial was to determine the symptomatic response of daily oral application of 360 mg CoQ(10) lasting 4 weeks on scored PD symptoms and visual function, measured with the Farnsworth-Munsell 100 Hue test (FMT), in 28 treated and stable PD patients. CoQ(10) supplementation provided a significant (P = 0.01) mild symptomatic benefit on PD symptoms and a significantly (F-(1,F-24) = 8.48, P = 0.008) better improvement of FMT performance compared with placebo. Our results indicate a moderate beneficial effect of oral CoQ10 supplementation in PD patients. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：201 / 204

页数：4

共 24 条

[1] DISTORTED COLOR DISCRIMINATION IN DE-NOVO PARKINSONIAN-PATIENTS [J].

BUTTNER, T ;

KUHN, W ;

MULLER, T ;

PATZOLD, T ;

HEIDBRINK, K ;

PRZUNTEK, H .

NEUROLOGY, 1995, 45 (02) :386-387

[2] Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy [J].

Chan, A ;

Reichmann, H ;

Kogel, A ;

Beck, A ;

Gold, R .

JOURNAL OF NEUROLOGY, 1998, 245 (10) :681-685

[3] Dopamine release in human ventral striatum and expectation of reward [J].

de la Fuente-Fernández, R ;

Phillips, AG ;

Zamburlini, M ;

Sossi, V ;

Calne, DB ;

Ruth, TJ ;

Stoessl, AJ .

BEHAVIOURAL BRAIN RESEARCH, 2002, 136 (02) :359-363

[4] Assessment of coenzyme Q10 tolerability in Huntington's disease [J].

Feigin, A ;

Kieburtz, K ;

Como, P ;

Hickey, C ;

Claude, K ;

Abwender, D ;

Zimmerman, C ;

Steinberg, K ;

Shoulson, I .

MOVEMENT DISORDERS, 1996, 11 (03) :321-323

[5] LOVASTATIN DECREASES COENZYME-Q LEVELS IN HUMANS [J].

FOLKERS, K ;

LANGSJOEN, P ;

WILLIS, R ;

RICHARDSON, P ;

XIA, LJ ;

YE, CQ ;

TAMAGAWA, H .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (22) :8931-8934

[6]

FUENTEFERNANDEZ R, 2002, EVAL HLTH PROF, V25, P387

[7] LOW PLATELET MITOCHONDRIAL COMPLEX-I AND COMPLEX-II/III ACTIVITY IN EARLY UNTREATED PARKINSONS-DISEASE [J].

HAAS, RH ;

NASIRIAN, F ;

NAKANO, K ;

WARD, D ;

PAY, M ;

HILL, R ;

SHULTS, CW .

ANNALS OF NEUROLOGY, 1995, 37 (06) :714-722

[8]

HARNOIS C, 1990, INVEST OPHTH VIS SCI, V31, P2473

[9] Vision in Parkinson's disease: what are the deficits and what are their origins? [J].

Harris, J .

NEURO-OPHTHALMOLOGY, 1998, 19 (03) :113-135

[10] PROPOSALS FOR SCORING AND ASSESSING 100-HUE TEST [J].

KINNEAR, PR .

VISION RESEARCH, 1970, 10 (05) :423-&

← 1 2 3 →